Truist Securities Downgrades Pacira BioSciences to Sell, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has downgraded Pacira BioSciences (NASDAQ:PCRX) from Buy to Sell and lowered the price target from $30 to $8.
August 13, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has downgraded Pacira BioSciences from Buy to Sell and significantly lowered the price target from $30 to $8.
The downgrade from Buy to Sell and the drastic reduction in the price target from $30 to $8 by Truist Securities is likely to negatively impact investor sentiment and lead to a short-term decline in PCRX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100